相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR
David W. Schoppy et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
A. Peasland et al.
BRITISH JOURNAL OF CANCER (2011)
Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs
Hiroko Onozuka et al.
CANCER SCIENCE (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
Luis I. Toledo et al.
MOLECULAR ONCOLOGY (2011)
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Philip M. Reaper et al.
NATURE CHEMICAL BIOLOGY (2011)
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Matilde Murga et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Luis I. Toledo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
GENOMIC INSTABILITY IN CANCER Strategies to improve radiotherapy with targeted drugs
Adrian C. Begg et al.
NATURE REVIEWS CANCER (2011)
Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
Oren Gilad et al.
CANCER RESEARCH (2010)
Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair
Meredith A. Morgan et al.
CANCER RESEARCH (2010)
The ATR barrier to replication-born DNA damage
Andres J. Lopez-Contreras et al.
DNA REPAIR (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Advanced pancreatic carcinoma: current treatment and future challenges
Anastasios Stathis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The role of radiotherapy in multimodal treatment of pancreatic carcinoma
Thomas B. Brunner et al.
RADIATION ONCOLOGY (2010)
Prospects for the Use of ATR Inhibitors to Treat Cancer
Jill M. Wagner et al.
PHARMACEUTICALS (2010)
Radiosensitization by Chir-124, a selective CHK1 inhibitor Effects of p53 and cell cycle checkpoints
Yungan Tao et al.
CELL CYCLE (2009)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53
Yaroslava Ruzankina et al.
NATURE GENETICS (2009)
Epidemiology of pancreatic cancer: an overview
Sara Raimondi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)
Class IPI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
Remko Prevo et al.
CANCER RESEARCH (2008)
Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer
Taro Okazaki et al.
CLINICAL CANCER RESEARCH (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
Florence Huguet et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer
DH Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer
A Jimeno et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
HL Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine
K Yokoi et al.
CLINICAL CANCER RESEARCH (2004)
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer
NE Martin et al.
CLINICAL CANCER RESEARCH (2004)
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
MJ Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Pancreatic tumors show high levels of hypoxia
AC Koong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
分享论文
